Genitourinary Cancer Clinical Trials

A listing of Genitourinary Cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 227 clinical trials
Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)

Substudy 03A is part of a larger research study that is testing experimental treatments for renal cell carcinoma (RCC). The larger study is the umbrella study (U03). The goal of substudy 03A is to evaluate the safety and efficacy of experimental combinations of investigational agents in participants with advanced first …

carcinoma
pembrolizumab
lenvatinib
major surgery
systemic therapy
  • 0 views
  • 16 Sep, 2021
  • 27 locations
Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B)

Substudy 03B is part of a larger research study that is testing experimental treatments for renal cell carcinoma (RCC). The larger study is the umbrella study (U03). The goal of substudy 03B is to evaluate the safety and efficacy of experimental combinations of investigational agents in participants with advanced second …

vegf
monoclonal antibodies
major surgery
tyrosine
kinase inhibitor
  • 4 views
  • 16 Sep, 2021
  • 27 locations
Ivosidenib in Treating Patients With Advanced Solid Tumors Lymphoma or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial)

This phase II Pediatric MATCH trial studies how well ivosidenib works in treating patients with solid tumors that have spread to other places in the body (advanced), lymphoma, or histiocytic disorders that have IDH1 genetic alterations (mutations). Ivosidenib may block the growth of cancer cells that have specific genetic changes …

bone marrow infiltration
nitrosourea
radiopharmaceutical
autologous stem cell infusion
metastatic disease
  • 37 views
  • 12 Sep, 2021
  • 90 locations
Evaluation of IPI-549 Combined With Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal Cell Carcinoma (MARIO-3)

MARIO-3 is a Phase 2 multi-arm combination cohort study designed to evaluate IPI-549, Infinity Pharmaceutical's first-in-class, oral immuno-oncology product candidate targeting immune-suppressive tumor-associated myeloid cells through selective inhibition of phosphoinositide-3-kinase (PI3K)-gamma, in combinations with Tecentriq and Abraxane (nab-paclitaxel) in front-line triple negative breast cancer (TNBC) and in combination with Tecentriq …

triple-negative breast cancer
estrogen receptor
gonadotropin
gilbert's syndrome
HER2
  • 23 views
  • 22 Sep, 2021
  • 22 locations
Testing AZD1775 in Advanced Solid Tumors That Have a Mutation Called SETD2

This phase II trial studies how well adavosertib works in treating patients with SETD2-deficient solid tumors that have spread to other places in the body (advanced/metastatic). Adavosertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

clear cell renal cell carcinoma
tumor cells
tyrosine
measurable disease
solid tumour
  • 37 views
  • 17 Sep, 2021
  • 19 locations
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902) or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib Versus Pembrolizumab and Lenvatinib for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)

The goal of this study is to evaluate the efficacy and safety of pembrolizumab plus belzutifan plus lenvatinib or pembrolizumab/quavonlimab plus lenvatinib versus pembrolizumab plus lenvatinib as first-line treatment in participants with advanced clear cell renal cell carcinoma (ccRCC). The primary hypotheses are (1) pembrolizumab plus belzutifan plus lenvatinib is …

carcinoma
clear cell renal cell carcinoma
pembrolizumab
lenvatinib
systemic therapy
  • 3 views
  • 26 Sep, 2021
  • 93 locations
Disease Burden and Biology Using Tumor Cell Free DNA in Metastatic Kidney Cancer

This study will assess whether DNA released by kidney cancer into the blood stream and urine of patients can be used to monitor tumor burden and tumor response to treatment in patients receiving immunotherapy

cancer
kidney cancer
measurable disease
carcinoma
  • 0 views
  • 12 Sep, 2021
  • 3 locations
Prospective Study to Evaluate the Blood Kinetics of Immune Cells and Immunosuppressive Cytokines After Exposure to an Immunity Checkpoint Inhibitor (ICI): Study of the Impact of Chemotherapy

Non-small cell lung cancer (NSCLC) is the most common histological form, accounting for 85% of all bronchopulmonary cancers (PBC). The advent of Immunity Checkpoint Inhibitors (ICIs) targeting Programmed cell Death-1 (PD-1) is changing current treatment algorithms. Preliminary results from work carried out in the Medical Oncology Department of the University …

gemcitabine
cancer chemotherapy
tumor cells
lung carcinoma
bladder tumor
  • 0 views
  • 12 Sep, 2021
  • 2 locations
Testing the Addition of a New Anti-cancer Drug Radium-223 Dichloride to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone the RadiCaL Study

This phase II trial studies whether adding radium-223 dichloride to the usual treatment, cabozantinib, improves outcomes in patients with renal cell cancer that has spread to the bone. Radioactive drugs such as radium-223 dichloride may directly target radiation to cancer cells and minimize harm to normal cells. Cabozantinib may stop …

cytokine therapy
warfarin
pet scan
karnofsky performance status
anticoagulants
  • 6 views
  • 27 Sep, 2021
  • 24 locations
A Study of DS-6000a in Subjects With Advanced Renal Cell Carcinoma and Ovarian Tumors

This clinical trial will evaluate DS-6000a in participants with advanced renal cell carcinoma (RCC) and ovarian cancer (OVC). The main goals of this study will be to investigate the recommended dose of DS-6000a that can be given safely to participants, assess the side effects of DS-6000a, and evaluate the effectiveness …

cancer
cancer of the ovary
carcinoma
advanced renal cell carcinoma
  • 0 views
  • 24 Sep, 2021
  • 5 locations